Art. 21a Directive (EU) 2001/83

In forcesince 20 Jan 2011cited 8×

In addition to the provisions laid down in Article 19, a marketing authorisation for a medicinal product may be granted subject to one or more of the following conditions:

(a)

to take certain measures for ensuring the safe use of the medicinal product to be included in the risk management system;

(b)

to conduct post-authorisation safety studies;

(c)

to comply with obligations on the recording or reporting of suspected adverse reactions which are stricter than those referred to in Title IX;

(d)

any other conditions or restrictions with regard to the safe and effective use of the medicinal product;

(e)

the existence of an adequate pharmacovigilance system;

(f)

to conduct post-authorisation efficacy studies where concerns relating to some aspects of the efficacy of the medicinal product are identified and can be resolved only after the medicinal product has been marketed. Such an obligation to conduct such studies shall be based on the delegated acts adopted pursuant to Article 22b while taking into account the scientific guidance referred to in Article 108a.

The marketing authorisation shall lay down deadlines for the fulfilment of these conditions where necessary.

  • Directive (EU) 2010/84Law

    … přijímat akty v přenesené pravomoci v souladu s článkem 290 Smlouvy o fungování EU, pokud jde o doplnění článků 21a a 22a směrnice 2001/83/ES. Komise by měla být zmocněna přijmout dodatečná opatření, v nichž budou …

  • Commission Implementing Regulation (EU) No 520/2012 of 19 June 2012 on the performance o…36Law

    … na základě povinností uložených příslušným vnitrostátním orgánem, agenturou nebo Komisí v souladu s články 21a a 22a směrnice 2001/83/ES a s články 10 a 10a nařízení (ES) č. 726/2004. 2. Držitel rozhodnutí o …

  • Regulation (EU) 2024/568Law

    … 726/2004 af sikkerhedsundersøgelser efter tilladelse til markedsføring som omhandlet i artikel 21a, litra b), eller artikel 22a, stk. 1, litra a), i direktiv 2001/83/EF eller i artikel 9, stk. 4, litra cb), eller artikel 10a, stk. 1, …

  • Commission Delegated Regulation (EU) No 357/2014 of 3 February 2014 supplementing Direct…1Law

    … artikel 21a, litra f), artikel 22a, stk. 1, litra b), i direktiv 2001/83/EF og artikel 9, stk. 4, litra cc), og artikel 10a, stk. 1, litra b), i forordning (EF) nr. 726/2004 a) hvis der er bekymring om visse aspekter af lægemidlets …

  • Gesetz über den Verkehr mit Arzneimitteln28Law

    … Inverkehrbringen beseitigt werden können, Wirksamkeitsstudien nach der Zulassung durchzuführen, die den Vorgaben in Artikel 21a Satz 1 Buchstabe f der Richtlinie 2001/83/EG entsprechen. (3b) Die zuständige Bundesoberbehörde kann nach …

  • Opinion of Advocate General Mengozzi delivered on 4 October 2018. Dr. August Wolff GmbH & Co. KG Arzneimittel and Remedia d.o.o. v European Decision

    With regard to the alleged impossibility of ordering additional studies on the risks of endometrial hyperplasia and the absence of explanations, in paragraph 207 of the judgment under appeal, of why the drafting frequency of five years for …

    4 Oct 2018 · 62016CC0680

  • Commission Delegated Regulation (EU) No 357/2014 of 3 February 2014 supplementing Direct…1Law

    … a post-authorisation efficacy study to be carried out by the holder of a marketing authorisation in accordance with Articles 21a(f) and 22a(1)(b) of Directive 2001/83/EC and Articles 9(4)(cc) and 10a(1)(b) of Regulation (EC) No …

  • Commission Implementing Regulation (EU) No 520/2012 of 19 June 2012 on the performance o…36Law

    … holder under obligations imposed by a national competent authority, the Agency or the Commission in accordance with Articles 21a and 22a of Directive 2001/83/EC and Articles 10 and 10a of Regulation (EC) No 726/2004. 2. The marketing …